Conba Pharma receives approval for throat clearing lozenges

Zhejiang Conba Pharmaceutical (SSE:600572) announced that it has been granted a Drug Registration Certificate by the National Medical Products Administration (NMPA) for its throat clearing lozenges. Classified as a Class 2 traditional Chinese medicine, the lozenges are indicated for treating acute pharyngitis symptoms related to lung heat and Yin deficiency. The company invested CNY 4,930 million in 2023 to acquire related technology and clinical trial documents from Suzhou Yuson Innovative Pharmaceutical. The company expects the approval and subsequent production of the lozenges to positively impact its product line and market competitiveness in the CNY 74.74 million throat medicine market, but cautions that sales and revenue remain uncertain.